{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:29Z","timestamp":1790138489074,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:05:58Z","timestamp":1750705558000},"page":"e709-e720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Maya","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Scarpetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.06.013_bib0001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.06.013_bib0002","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2025.06.013_bib0003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1074-7613(01)00234-5","article-title":"The immunological synapse of CTL contains a secretory domain and membrane bridges","volume":"15","author":"Stinchcombe","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2025.06.013_bib0004","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.clml.2025.06.013_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2025.06.013_bib0006","first-page":"3","article-title":"Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system","volume":"1","author":"Hayden","year":"1994","journal-title":"Ther Immunol"},{"key":"10.1016\/j.clml.2025.06.013_bib0007","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2025.06.013_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clml.2025.06.013_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11912-019-0759-5","article-title":"Bispecific antibodies in hematologic malignancies: when, to whom, and how should Be best used?","volume":"21","author":"Demichelis-Gomez","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2025.06.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2025.06.013_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2025.06.013_bib0012","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.clml.2025.06.013_bib0013","first-page":"e3486","article-title":"Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer","volume":"10","author":"Tariq","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.clml.2025.06.013_bib0014","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.clml.2025.06.013_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells","volume":"22","author":"Levine","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.clml.2025.06.013_bib0016","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2025.06.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.clml.2025.06.013_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","article-title":"Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy","volume":"40","author":"Dabas","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2025.06.013_bib0019","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-018-0840-y","article-title":"Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy","volume":"17","author":"Pang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2025.06.013_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.06.013_bib0021","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"P30\u2003SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.06.013_bib0023","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2023.41.16_suppl.8039","article-title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study","volume":"41","author":"Mohty","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0024","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0025","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1200\/JCO.2023.41.16_suppl.8038","article-title":"Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Sun","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0026","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0027","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0028","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.06.013_bib0029","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0031","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0032","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2023-179147","article-title":"Safety and Efficacy of GPRC5D CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0033","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967684.98632.87","article-title":"S193: BMS-986393 (CC-95266), A G PROTEIN\u2013COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)\u2013TARGETED CAR T-CELL THERAPY FOR RELAPSED\/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY","volume":"7","author":"Bal","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.06.013_bib0034","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: A phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0035","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1182\/bloodadvances.2024014308","article-title":"Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms","volume":"8","author":"Sperling","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.06.013_bib0036","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0037","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0038","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0039","article-title":"CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASSREFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I\/II CAMMA 2 STUDY","author":"Kumar","year":"2024"},{"key":"10.1016\/j.clml.2025.06.013_bib0040","doi-asserted-by":"crossref","first-page":"151712","DOI":"10.1016\/j.soncn.2024.151712","article-title":"Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma","volume":"40","author":"Catamero","year":"2024","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.clml.2025.06.013_bib0041","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.clml.2025.06.013_bib0042","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.clml.2025.06.013_bib0043","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2025.06.013_bib0044","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.06.013_bib0045","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/bmt.2016.229","article-title":"Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab","volume":"51","author":"Cho","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.clml.2025.06.013_bib0046","article-title":"Forecasting the cytokine storm following systemic interleukin (IL)-2 administration","volume":"2","author":"Panelli","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0047","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0048","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1091581815584918","article-title":"Cytokines: The Good, the Bad, and the Deadly","volume":"34","author":"Ramani","year":"2015","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.clml.2025.06.013_bib0049","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0167-5699(89)90085-6","article-title":"The cytokine network","volume":"10","author":"Balkwill","year":"1989","journal-title":"Immunol Today"},{"key":"10.1016\/j.clml.2025.06.013_bib0050","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbamcr.2011.06.019","article-title":"Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines","volume":"1813","author":"Schmitz","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2025.06.013_bib0051","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clml.2025.06.013_bib0052","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2025.06.013_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2025.06.013_bib0054","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1073\/pnas.0501794102","article-title":"IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation","volume":"102","author":"McLoughlin","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2025.06.013_bib0055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0056","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.celrep.2014.07.008","article-title":"IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function","volume":"8","author":"Bottcher","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2025.06.013_bib0057","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0058","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2025.06.013_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2025.06.013_bib0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2025.06.013_bib0061","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2025.06.013_bib0062","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.06.013_bib0063","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2025.06.013_bib0064","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0065","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.06.013_bib0066","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.013_bib0067","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2025.06.013_bib0068","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0069","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CCM.0b013e3182a27598","article-title":"Investigating conflict in ICUs-is the clinicians' perspective enough?","volume":"42","author":"Schuster","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0070","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Donk","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0071","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2025.06.013_bib0072","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0073","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0074","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.06.013_bib0076","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0077","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1182\/blood-2024-193025","article-title":"Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"144","author":"Davis","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0078","unstructured":"Rajkumar, V. Accessed June 10, 2025. https:\/\/www.msmart.org\/mm-treatment-guidelines (2024)."},{"key":"10.1016\/j.clml.2025.06.013_bib0079","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2025.06.013_bib0080","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0081","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0082","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"issue":"150","key":"10.1016\/j.clml.2025.06.013_bib0083","article-title":"Cellular immunotherapy for refractory hematological malignancies","volume":"11","author":"Reagan","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0084","unstructured":"FDA approval brings first gene therapy to the United States. U.S. Food & Drug Administration (2017)."},{"key":"10.1016\/j.clml.2025.06.013_bib0085","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0086","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.06.013_bib0087","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1182\/blood-2023-179620","article-title":"Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis","volume":"142","author":"Bajwa","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0088","doi-asserted-by":"crossref","first-page":"623610","DOI":"10.3389\/fimmu.2021.623610","article-title":"Therapeutic Potential of TNFalpha and IL1beta Blockade for CRS\/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2025.06.013_bib0089","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"96","key":"10.1016\/j.clml.2025.06.013_bib0090","article-title":"A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0091","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2025.06.013_bib0092","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.013_bib0093","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.06.013_bib0094","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-199957020-00006","volume":"57","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2025.06.013_bib0095","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.06.013_bib0096","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/jha2.906","article-title":"Fast but not so furious\": A condensed step-up dosing schedule of teclistamab for relapsed\/refractory multiple myeloma","volume":"5","author":"Graf","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.06.013_bib0097","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.013_bib0098","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-017-0074-5","article-title":"Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL","volume":"6","author":"Nagele","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2025.06.013_bib0099","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.013_bib0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-019-0753-y","article-title":"Cytokine release Syndrome with the Novel treatments of acute lymphoblastic leukemia: pathophysiology, prevention, and treatment","volume":"21","author":"Aldoss","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2025.06.013_bib0101","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2022-159381","article-title":"Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.013_bib0102","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.013_bib0103","article-title":"Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration","volume":"OP2400489","author":"Sandahl","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2025.06.013_bib0104","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2023-185257","article-title":"Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma","volume":"142","author":"Rifkin","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:18:48Z","timestamp":1762600728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025002216"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}